Background Deep vein thrombosis (DVT) and pulmonary embolism are collectively known
as venous thromboembolism (VTE), which is a common vascular disease and a major cause …

Background In phase III trials, rivaroxaban demonstrated non-inferiority over
enoxaparin/warfarin to prevent recurrent venous thromboembolism (VTE), with a reduction …

A paucity of real-world data evaluating rivaroxaban in provoked venous thromboembolism
(VTE) exists. We assessed the effectiveness and safety of rivaroxaban versus warfarin in …

The efficacy and safety or rivaroxaban versus enoxaparin/vitamin K antagonist for treatment
and prevention recurrence of venous thromboembolism (VTE) was demonstrated in the …

We investigated three-month clinical outcomes in patients with venous thromboembolism
(VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice …

Background Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being
increasingly used in routine clinical practice because of their fixed dosing and favourable …

Introduction Rivaroxaban is an oral direct factor Xa inhibitor that is noninferior to warfarin in
the prevention of recurrent venous thromboembolism (VTE). Whether rivaroxaban is cost …

Aims To investigate the risk of all-cause mortality, recurrent venous thromboembolism (VTE),
and hospitalized bleeding in patients with VTE treated with either rivaroxaban or apixaban …

Background Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …

Background Standard treatment for venous thromboembolism (VTE) consists of a heparin
combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for …